Last reviewed · How we verify
Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Bat | bat | Pfizer | Unknown | Unknown |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy:
- Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy treatment updates — RSS
- Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy treatment updates — Atom
- Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-partial-onset-seizures-with-and-without-secondary-generalization-in-patients-12-years-of-age-and-older-with-epilepsy. Accessed 2026-06-10.
Related
- Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing